|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00588549 |
|
Date of registration:
|
24/12/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases
|
|
Scientific title:
|
Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases |
|
Date of first enrolment:
|
July 1998 |
|
Target sample size:
|
204 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00588549 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Yuman Fong, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Memorial Sloan-Kettering Cancer Center |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- initial diagnosis of colorectal carcinoma confirmed by the Pathology Department of
Memorial Hospital or by diagnostic barium enema if the primary tumor is still in
place.
- a candidate for liver resection for metastatic colorectal cancer as defined by
members of the Department of Surgery of Memorial Hospital. Patients with metastatic
colorectal cancer isolated to the colon, rectum, or liver are eligible. In addition,
patients with limited, resectable pulmonary metastases are eligible.
Exclusion Criteria:
- Patients must not be pregnant; females of child bearing age must use an adequate form
of contraception.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Colorectal Carcinoma
|
|
Primary Outcome(s)
|
|
To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.
[Time Frame: conclusion of the study]
|
|
Secondary Outcome(s)
|
|
To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases.
[Time Frame: conclusion of the study]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|